BHC
Bausch Health Companies Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 27 to Mar 3 ▼ 3 days of insider sells: $115.0K by 1 insider, avg $5.85
- May 19 ▼ 1 insider sell $132.8K at $5.43
- Aug 6 Leadership: Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
- Aug 19 ▼ 1 insider sell $258.9K at $7.03
- Aug 27 Contract: Bausch Health's Ortho Dermatologics Announces the 2026 Asp…
- Oct 28 ▲ Bausch Health reported Q3 2026 revenue of $2.94B (up 10% YoY) and ad…
- Oct 28 ▲ Buyback: Bausch Health Announces US$50 Million Share Repurchase Pro…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $506.7K.
- InstitutionsMIXED
Q3 2026: 23 added (0 new), 19 trimmed or exited.
- AnalystsBEARISH
0 of 8 rate it Buy or better. Median target $8.00 (−5%).
- EstimatesRISING
Current-quarter EPS estimate $1.274 → $1.309 over 90 days. 1 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −10.1% to 7.41M shares. 1.2 days to cover, ≈2.0% of shares.
- TrendUPTREND
27% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $26.8M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | $17.5M |
| MARSHALL WACE, LLP | DOUBLED | $15.0M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $12.0M |
| MACKENZIE FINANCIAL CORP | DOUBLED | $6.8M |
| Qube Research & Technologies Ltd | TRIM | $4.9M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $4.7M |
| Walleye Capital LLC | DOUBLED | $3.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analystsPrice is inside the target range. Median implies −5%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Barclays MAINTAIN | Equal-Weight |
| Oct 29, 2026 | Jefferies MAINTAIN | Hold |
| Oct 29, 2026 | RBC Capital MAINTAIN | Sector Perform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Paulson John Director Sep 30, 2026 | AWARD | $62.5K |
LEUNG SANDRA Director Sep 30, 2026 | AWARD | $33.7K |
WECHSLER AMY B Director Sep 30, 2026 | AWARD | $6.9K |
Lenar Aimee J. President, US Pharma Aug 19, 2026 | SELL | $258.9K |
Lenar Aimee J. President, US Pharma Jul 17, 2026 | TAX W/H | $25.4K |
Lenar Aimee J. President, US Pharma Jul 15, 2026 | TAX W/H | $114.4K |
LEE STEVEN HYOSIG SVP, Controller & CAO Jul 14, 2026 | TAX W/H | $14.8K |
WECHSLER AMY B Director Jun 30, 2026 | AWARD | $6.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $1.31 | $1.17–$1.49 | +0.8% | $2.8B |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | $4.91 | $4.32–$5.33 | +9.7% | $11.0B |
| Next FY | $4.34 | $4.00–$4.77 | +3.5% | $11.0B |
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
3 filings · 2 press releases · 1 bullish · 0 bearish · 2 neutral- BULLISH 8-KOct 28, 2026
Bausch Health reported Q3 2026 revenue of $2.94B (up 10% YoY) and adjusted EPS of $1.77, beating…
The raised guidance and strong cash generation signal improving fundamentals, but the Solta Medical organic decline and the $50M buyback (small relative to $2.4B market cap) warrant monitoring. The…
- NEUTRAL PRESS RELEASEOct 28, 2026
Bausch Health announced a $50 million share repurchase program to manage dilution from employee…
The buyback is modest and primarily anti-dilutive, not a capital return signal. Monitor actual repurchase execution in future filings; the company is not obligated to buy any shares. The strong Q3…
- NEUTRAL PRESS-RELEASEOct 6, 2026
Bausch Health Companies Inc. announced it will report its Q3 2026 results on October 28, 2026.
- NEUTRAL PRESS RELEASEAug 27, 2026
Bausch Health announced the recipients of its 2026 Aspire Higher Scholarship Program, awarding six…
This is a non-material press release. No trading action is warranted based on this announcement.
All BHC filing & press-release reports (5)
- PRESS-RELEASE reportOct 28, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 6, 2026
- PRESS-RELEASE reportAug 27, 2026
- DEFA14A reportApr 8, 2026